TY - JOUR
T1 - Impact of amoxicillin therapy on resistance selection in patients with community-acquired lower respiratory tract infections
T2 - A randomized, placebo-controlled study
AU - Malhotra-Kumar, Surbhi
AU - Van Heirstraeten, Liesbet
AU - Coenen, Samuel
AU - Lammens, Christine
AU - Adriaenssens, Niels
AU - Kowalczyk, Anna
AU - Godycki-Cwirko, Maciek
AU - Bielicka, Zuzana
AU - Hupkova, Helena
AU - Lannering, Christina
AU - Mölstad, Sigvard
AU - Fernandez-Vandellos, Patricia
AU - Torres, Antoni
AU - Parizel, Maxim
AU - Ieven, Margareta
AU - Butler, Chris C.
AU - Verheij, Theo
AU - Little, Paul
AU - Goossens, Hermanon
AU - Frimodt-Møller, Niels
AU - Bruno, Pascale
AU - Hering, Iris
AU - Lemiengre, Marieke
AU - Loens, Katherine
AU - Malmvall, Bo Eric
AU - Muras, Magdalena
AU - Romano, Nuria Sanchez
AU - Prat, Matteu Serra
AU - Svab, Igor
AU - Swain, Jackie
AU - Tarsia, Paolo
AU - Leus, Frank
AU - Veen, Robert
AU - Worby, Tricia
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Objectives: To determine the effect of amoxicillin treatment on resistance selection in patients with community-acquired lower respiratory tract infections in a randomized, placebo-controlled trial. Methods: Patients were prescribed amoxicillin 1 g, three times daily (n = 52) or placebo (n = 50) for 7 days. Oropharyngeal swabs obtained before, within 48 h post-treatment and at 28-35 days were assessed for proportions of amoxicillin-resistant (ARS; amoxicillin MIC ≥2 mg/L) and -non-susceptible (ANS; MIC ≥0.5 mg/L) streptococci. Alterations in amoxicillin MICs and in penicillin-binding-proteins were also investigated. ITT and PP analyses were conducted. Results: ARS and ANS proportions increased 11- and 2.5-fold, respectively, within 48 h post-amoxicillin treatment compared with placebo [ARS mean increase (MI) 9.46, 95% CI 5.57-13.35; ANS MI 39.87, 95% CI 30.96-48.78; P <0.0001 for both]. However, these differences were no longer significant at days 28-35 (ARS MI -3.06, 95% CI -7.34 to 1.21; ANS MI 4.91, 95% CI -4.79 to 14.62; P > 0.1588). ARS/ANS were grouped by pbp mutations. Group 1 strains exhibited significantly lower amoxicillin resistance (mean MIC 2.8 mg/L, 95% CI 2.6-3.1) than group 2 (mean MIC 9.3 mg/L, 95% CI 8.1-10.5; P <0.0001). Group 2 strains predominated immediately post-treatment (61.07%) and although decreased by days 28-35 (30.71%), proportions remained higher than baseline (18.70%; P = 0.0004). Conclusions: By utilizing oropharyngeal streptococci as model organisms this study provides the first prospective, experimental evidence that resistance selection in patients receiving amoxicillin is modest and short-lived, probably due to 'fitness costs' engendered by high-level resistance-conferring mutations. This evidence further supports European guidelines that recommend amoxicillin when an antibiotic is indicated for community-acquired lower respiratory tract infections.
AB - Objectives: To determine the effect of amoxicillin treatment on resistance selection in patients with community-acquired lower respiratory tract infections in a randomized, placebo-controlled trial. Methods: Patients were prescribed amoxicillin 1 g, three times daily (n = 52) or placebo (n = 50) for 7 days. Oropharyngeal swabs obtained before, within 48 h post-treatment and at 28-35 days were assessed for proportions of amoxicillin-resistant (ARS; amoxicillin MIC ≥2 mg/L) and -non-susceptible (ANS; MIC ≥0.5 mg/L) streptococci. Alterations in amoxicillin MICs and in penicillin-binding-proteins were also investigated. ITT and PP analyses were conducted. Results: ARS and ANS proportions increased 11- and 2.5-fold, respectively, within 48 h post-amoxicillin treatment compared with placebo [ARS mean increase (MI) 9.46, 95% CI 5.57-13.35; ANS MI 39.87, 95% CI 30.96-48.78; P <0.0001 for both]. However, these differences were no longer significant at days 28-35 (ARS MI -3.06, 95% CI -7.34 to 1.21; ANS MI 4.91, 95% CI -4.79 to 14.62; P > 0.1588). ARS/ANS were grouped by pbp mutations. Group 1 strains exhibited significantly lower amoxicillin resistance (mean MIC 2.8 mg/L, 95% CI 2.6-3.1) than group 2 (mean MIC 9.3 mg/L, 95% CI 8.1-10.5; P <0.0001). Group 2 strains predominated immediately post-treatment (61.07%) and although decreased by days 28-35 (30.71%), proportions remained higher than baseline (18.70%; P = 0.0004). Conclusions: By utilizing oropharyngeal streptococci as model organisms this study provides the first prospective, experimental evidence that resistance selection in patients receiving amoxicillin is modest and short-lived, probably due to 'fitness costs' engendered by high-level resistance-conferring mutations. This evidence further supports European guidelines that recommend amoxicillin when an antibiotic is indicated for community-acquired lower respiratory tract infections.
UR - http://www.scopus.com/inward/record.url?scp=84994517934&partnerID=8YFLogxK
U2 - 10.1093/jac/dkw234
DO - 10.1093/jac/dkw234
M3 - Article
C2 - 27353466
AN - SCOPUS:84994517934
SN - 0305-7453
VL - 71
SP - 3258
EP - 3267
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
IS - 11
ER -